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tive prognostic microenvironmental components (CD68-, 
PD-1- and granzyme B-positive cells) was of independent 
prognostic significance (p = 0.002).  Conclusion: Increased 
numbers of CD68-positive tumor macrophages indicate an 
adverse overall outcome in HL. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Classical Hodgkin lymphoma (cHL) is a lymphoid neo-
plasm consisting of mononuclear Hodgkin and multinu-
clear Reed-Sternberg cells (HRSC) embedded in a non-
neoplastic background infiltrate of small lymphocytes, 
eosinophilic and neutrophilic granulocytes, histiocytes, 
plasma cells, fibroblasts and collagen fibers  [1] . It is the 
paradigm of a formerly lethal neoplastic disease that be-
came curable with the introduction of modern multimod-
al therapies in the 1970s. With risk- and response-adapted 
multimodal therapy, over 85% of cHL patients achieve a 
long-lasting and complete remission  [2] . Nevertheless, 
about 3% of stage I and II and about 7% of stage III and 
IV cases present with refractory disease, and another 10–
15% relapse, requiring more intensive treatments  [3] . A 
drawback of the impressive achievements in cHL treat-
ment is the increasing late toxicity, particularly the high 
incidence of secondary malignancies, such as therapy-re-
lated myeloid neoplasms, breast and lung cancer and car-
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 Abstract 
 Objective: Classical Hodgkin lymphoma (HL) consists of 
neoplastic Hodgkin and Reed-Sternberg cells (HRSC) and a 
nonneoplastic micromilieu that greatly outnumbers the 
HRSC. Studies on HRSC-related prognostic biomarkers have 
been unsuccessful, but the microenvironmental composi-
tion is of prognostic importance. Recently, the number of 
CD68-positive macrophages was correlated with adverse 
survival in HL, and there was a call to validate these results. 
 Methods: We utilized immunohistochemistry to analyze the 
prognostic importance of the CD68-positive macrophage 
number compared to other cellular environmental compo-
nents in an unselected series of 105 HLs in tissue microarrays. 
 Results: Applying a cutoff score of  1 0.82% tumor macro-
phages, cases with increased numbers showed worse overall 
survival (mean 185 months, median 192) compared to cases 
with lower numbers (mean 285 months, median not reached). 
Eleven of 62 patients with  ^  0.82% tumor macrophages 
died, compared to 19 of 43 with  1 0.82% (p  ! 0.001). The num-
ber of macrophages correlated with a low FOXP3-/high gran-
zyme B-/high PD-1-positive micromilieu and patient age, but 
did not have independent prognostic significance. A combi-
nation background score taking into consideration all nega-
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diovascular diseases  [4] . Thus, it is important to be able to 
predict/identify patients who are treatment resistant and/
or have a higher risk of relapse and find alternative thera-
peutic options. In addition, patients who might be over-
treated by the current treatment regimens must be identi-
fied to reduce treatment-associated toxicity.
 Prior to the introduction of modern therapy protocols, 
histological type and nodular sclerosis grading were pre-
dictive for disease-specific outcome in cHL  [5–8] . Today, 
disease stage, presence of B symptoms, patient clinical 
history, including risk factors such as coincidental HIV 
infection, and laboratory parameters are the most impor-
tant predictive factors  [9, 10] . Studies searching for a 
meaningful HRSC-related phenotypic prognostic bio-
marker in cHL are contradictory and poorly reproducible 
 [1, 11, 12] . Contrary to HRSC-related biomarkers, reactive 
cellular environment characteristics seem to be of greater 
prognostic significance in cHL  [13–19] . Importantly, cHL 
lymphomagenesis is more closely related to the cellular 
background infiltrate than in other lymphomas. HRSC 
produce many cytokines and chemokines, resulting in 
the influx and activation of CD4+ cells and histiocytes; 
conversely, HRSC respond to the chemokines and growth 
factors produced by these surrounding cells, the latter 
providing essential feedback signals to stimulate prolif-
eration and inhibit apoptosis in HRSC  [20, 21] . A possible 
prognostic role of macrophages and histiocytes in cHL 
was suggested decades ago  [22–24] . A recent gene expres-
sion profiling study on an unselected cHL collective with 
subsequent immunohistochemical verification on a col-
lective enriched for treatment failures showed an impor-
tant correlation between the number of CD68-positive 
macrophages and adverse disease-specific survival (DSS) 
and worse outcome after secondary high-intensity thera-
py with autologous stem cell support, but results have 
thus far not been validated in an independent collective 
 [25] . Therefore, we systematically analyzed the prognos-
tic importance of the number of CD68-positive macro-
phages in an unselected series of 105 clinically and histo-
pathologically well-characterized cHLs in tissue micro-
arrays (TMAs).
 Materials and Methods 
 We used a patient set of our previously reported TMA collec-
tive  [19, 26] that met the following criteria: complete clinical doc-
umentation, presence of at least 5 unequivocal HRSC/case on the 
examined slides and presence of at least 1 CD68-positive cell/case 
on the examined slides. Only 105 of the initial 259 cases could be 
considered based on these criteria.
 Patients 
 cHL cases (n = 105) diagnosed between 1974 and 2000 and
reclassified according to the World Health Organization 2008 
criteria were collected from the archives of the Institutes of Pa-
thology at the University Hospitals of Basel, Switzerland, and 
Innsbruck, Austria. Paraffin blocks were selected based on 
availabil ity and preservation. Clinical and follow-up data (sum-
marized in table 1) were obtained from chart reviews. Retrieval 
of tissue and clinical data was performed according to the regula-
tions of the local institutional review boards and data safety laws. 
Treatment was either standard or consistent with the investiga-
tional protocols active during the time the patients were diag-
nosed. Patients were staged surgically as stage I or II when radio-
therapy (RT) was administered as the sole treatment. Otherwise, 
patients were staged clinically and treated with risk-adapted 
treatment strategies according to the protocols of the German 
Hodgkin Study Group valid at the time of diagnosis. In advanced 
stages, RT was applied for treatment of residual disease or pri-
mary bulky disease  [27, 28] . Disease remission was defined as 
absence of disease for at least 1 month as determined by labora-
tory and imaging studies as well as physical examination. Disease 
relapse was defined as disease progression occurring at least 1 
month after achieving disease remission. Treatment failure was 
defined as disease relapse or primary treatment resistance; the 
latter was not observed in the present collective. Overall survival 
(OS) was defined as the time from initial diagnosis to death or the 
last follow-up examination or other patient contact. DSS was de-
fined as the time from initial diagnosis to death from lymphoma 
or the last follow-up examination or other patient contact. Re-
lapse-free survival (RFS) was defined as the time from initial di-
agnosis to disease relapse or the last follow-up examination or 
other patient contact without imaging, clinical or anamnestic ev-
idence of disease recurrence.
 TMA Construction 
 The TMAs were constructed and validated as described else-
where  [19, 26] . Two cores from every sample were arrayed. The 
construction of the TMAs was approved by the institutional re-
view boards of the participating centers at the time of case sub-
mission, and cases have been kept anonymous to meet the legal 
and ethical requirements for their use in the present study.
 Immunohistochemical Evaluation 
 The slides were immunohistochemically stained for CD68 us-
ing an automated immunostainer (Nexes, Ventana, USA), utiliz-
ing the PGM1 antibody from Dako (M0876; 1: 200; antigen re-
trieval with citrate buffer, pH 6, in a microwave oven at 100  °  C for 
15 min). The total number of cells and CD68-stained cells on each 
array spot was counted at  ! 200 magnification. The percentage of 
CD68-positive cells for each spot was subsequently extracted. The 
mean percentage over both spots, provided that both contained 
HRSC, was considered for final statistical analysis, except for cas-
es in which the difference between both spots exceeded 1% or 
would lead to reclassification of a case as either negative or posi-
tive when considering the cutoff score for CD68-positive tumor 
macrophages. In both of the latter instances, the HRSC-richer ar-
ray spot was further considered (see Results). Details on FOXP3, 
granzyme B and PD-1 staining have been reported previously  [18, 
19] . To assess the reproducibility of the CD68 data, comparison 
between the results of two observers (A.T. and M.S.M.) in one 
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third of the cases was performed in a blinded fashion and assessed 
using interclass correlation coefficients.
 Statistics 
 Statistical analysis, including data description, was performed 
using the Statistical Package of Social Sciences 15.0 software (Chi-
cago, Ill., USA). The degree of agreement between observers was 
evaluated by interclass correlation coefficients, using Cronbach’s 
alpha reliability analysis, with alpha  1 0.75 indicating very good 
reproducibility. Spearman rank correlation coefficients were used 
to analyze relationships between markers and/or clinical vari-
ables. The Mann-Whitney U and Kruskal-Wallis tests were ap-
plied, where appropriate, to assess mean differences between 
groups. The prognostic performance of the variables and deter-
mination of optimal cutoff values of continuous variables were 
established by receiver operating characteristic (ROC) curves 
plotting sensitivity versus 1 – specificity. The optimal cutoff point 
was calculated using Youden’s index (Y), where Y = sensitivity + 
specificity – 1, since this method can be applied when there is no 
particular requirement for sensitivity and/or specificity  [29] . ROC 
analysis was applied for OS, DSS and RFS. Survival was then ana-
lyzed by the Kaplan-Meier method applying the cutoff values cal-
culated by ROC/Y. Survival results from the present study as well 
as prognostic factors already established in the study collective 
 [18, 19] , for which the ROC or Kaplan-Meier methods suggested 
statistical (p  ! 0.05) or borderline significance (p  ! 0.1), were fur-
ther considered in the multivariate analysis using a Cox regres-
sion model.
 Results 
 Patients 
 Within the median follow-up period of 142 months, 
72% of the patients survived, 10% died from lymphoma 
and 18% died from other causes such as second malig-
nancies (n = 11), cardiovascular events (n = 6), infections 
(n = 2) and trauma (n = 1), the former 3 being highly prob-
ably attributable to lymphoma therapy. Mean OS was 243 
months [95% confidence interval (CI) 218–268], and 
mean DSS was 297 months (95% CI 278–318). The average 
time to first relapse was 56 months (range 7–240). For the 
prognostic significance of basic clinicopathological vari-
ables, see  table 1 .
 Assessment of CD68-Positive Tumor Macrophages 
 Immunohistochemistry is shown in  figure 1 . Cron-
bach’s alpha for interobserver reproducibility for a given 
case was 0.829. Cronbach’s alpha for agreement between 
results assessed on both TMA spots of a given case was 
0.802. Cases in which the difference between both spots/
cores exceeded 1% or would have led to reclassification of 
a case as either negative or positive when considering the 
cutoff score for CD68-positive tumor macrophages (n = 
Table 1.  Basic patient characteristics
Variables Cases, n (%) Prognostic
significance for
OS DSS RFS
Gender
Male 54 (51) n.s. n.s. n.s.
Female 51 (49)
Age, years
Mean/median/range 37/34/13–87 <0.001 n.s. n.s.
<55 87 (83)
≥55 18 (17)
Disease stage
I 16 (15) 0.057 n.s. 0.049
II 50 (49)
III 22 (21)
IV 17 (15)
B symptoms
No 62 (59) n.s. n.s. n.s.
Yes 43 (41)
cHL subtype
Nodular sclerosis 60 (57) n.s. n.s. n.s.
Mixed cellularity 32 (30)
Lymphocyte rich 3 (3)
Lymphocyte depleted 2 (2)
Unclassifiable 8 (8)
EBV association
No 85 (81) n.s. n.s. n.s.
Yes 20 (19)
Therapy
RT 27 (26) n.s. n.s. n.s.
COPP 18 (17)
COPP + RT 30 (29)
ABVD 14 (13)
ABVD + RT 16 (15)
Follow-up, months
Mean/median/range              146/142/
12–331
n.a.
Relapses 29 n.s. <0.001 n.a.
Causes of death
Death with/from disease 10 n.a.
Second malignancy 11
Cardiovascular disease 6
Other (infection, trauma) 3
EBV = Epstein-Barr virus; n.a. = not applicable; n.s. = not sig-
nificant.
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26) were reanalyzed on a double-headed microscope by 
both investigators. The different distribution of CD68-
positive tumor macrophages could be reproduced after 
reevaluation in all these cases and was attributable to the 
absence or paucity of HRSC on either the first or second 
arrayed spot. Importantly, in these cases, specific consid-
eration of the prognostic value of the number of CD68-
positive tumor macrophages assessed on either the first 
or the second arrayed spot showed that only the number 
assessed on the spot containing HRSC or enriched in 
HRSC was of prognostic importance. In such equivocal 
cases, results assessed on the HRSC-richer array spot 
were considered further. For descriptive results, see  ta-
ble 2 .
 Correlations 
 CD68-positive tumor macrophage numbers correlat-
ed with patient age (  = 0.484, p  ! 0.001; 16 of 18 patients 
aged  6 55 years had increased numbers of CD68-positive 
tumor macrophages compared to 28 of 87 patients young-
er than 55) and with the number of tumor-infiltrating 
granzyme B-positive lymphocytes (  = 0.260, p = 0.025) 
and correlated inversely with the number of tumor-infil-
trating FOXP3-positive lymphocytes (  = –0.351, p = 
0.004). There were no other significant correlations.
 Prognostic Factors 
 ROC analysis suggested a prognostic role for OS, but 
not DSS or RFS, for the numbers of CD68-positive tumor 
macrophages (p = 0.038) and granzyme B- (p = 0.012), 
PD-1- (p = 0.027) and FOXP3-positive tumor-infiltrat-
ing lymphocytes (p = 0.036). A prognostic role for RFS 
and DSS was also found for FOXP3-positive tumor-infil-
trating lymphocytes (p = 0.012 and 0.059, respectively) 
 [18, 19] . The respective ROC curves considering OS are 
shown in  figure 2 . With respect to OS, the area under the 
ROC curve for CD68-positive macrophages was 0.660 
(95% CI 0.514–0.806), indicating that consideration of 
CD68-positive macrophage numbers is a significant im-
provement over a random guess. The Y value pointed to 
 1 0.82% CD68-positive tumor macrophages as being the 
most relevant cutoff score with respect to OS, with a 
prognostic sensitivity of 74% and a specificity of 65%. 
Applying this cutoff score, Kaplan-Meier analysis showed 
worse OS for cHL with increased numbers of CD68-pos-
itive tumor macrophages (mean 185 months, 95% CI 
142–227, median 192 months) compared to cases with 
lower numbers (mean 285 months, 95% CI 259–311, me-
dian not reached). Eleven of 62 patients with  ^  0.82% 
CD68-positive tumor macrophages died, compared to 19 
of 43 with  1 0.82% CD68-positive tumor macrophages
 (p  ! 0.001;  fig. 3 ). There were significant differences with 
regard to the causes of death between cases with in-
A B
 Fig. 1.  A cHL with  ! 0.82% CD68-positive 
tumor macrophages.  B A case with  1 0.82% 
CD68-positive tumor macrophages. Im-
munoperoxidase stain.  ! 200. 
Table 2.  Quantitative results
cHL subtype Cases
n
CD68+ tumor
macrop hages, %
Cases with 
>0.82% 
mean 8 SD range
Nodular sclerosis 60 1.582.2 0.0–7.9 21 (35%)
Mixed cellularity 32 2.082.3 0.0–8.6 18 (60%)
Lymphocyte rich 3 0.180.07 0.0–0.13  0
Lymphocyte depleted 2 1.380.9 0.7–2.0  1 (50%)
Unclassifiable 8 1.481.6 0.0–3.3  3 (38%)
p value n.s. n.s.
n.s. = Not significant.
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creased and decreased tumor macrophages, with a par-
ticular accumulation of second malignancies and infec-
tions among those patients with increased tumor macro-
phages ( table 3 ). Rounding up of the cutoff score from 
 ^  0.82 to  ^  1%, which we assumed to represent a more 
practicable cutoff score, would have reclassified 3 of the 
studied cases from the prognostically adverse to the 
prognostically favorable group. Since 2 of these patients 
died from their disease, ROC analysis indicated that ap-
plication of such a cutoff score rather than  ^  0.82% to 
our collective would lead to a drop in prognostic sensitiv-
ity to 63% without increasing the specificity. Thus, 
though we acknowledge that a cut-off score of 1% is more 
practical, for the purposes of our study, we strictly ad-
hered to the  ^  0.82% cutoff, as suggested by ROC/Y. Ap-
plication of the cutoffs suggested by Steidl et al.  [25] , i.e. 
0 to  ! 5%, 5–25% and  1 25%, led to analogous results, but 
the absolute number of the collective with a CD68-posi-
tive cell number over the cutoff was smaller; thus, the 
prognostic specificity of adverse events for a cutoff of 
 6 5% CD68-positive tumor macrophages rose to 92%, 
but the sensitivity dropped to 16%. In our collective, 
which was not specifically enriched for treatment fail-
ures, we did not observe a single case with  1 9% CD68-
positive tumor macrophages.
 When analyzed in subgroups according to the clinico-
pathological variables listed in  table 1 , the negative prog-
nostic effect of an increased number of CD68-positive 
tumor macrophages retained its significance for both 
genders (males p = 0.008, females p = 0.015), patients 
younger than 55 years (p = 0.046), stage II (p = 0.001) and 
III disease (p = 0.09), patients with and without B symp-
toms (p = 0.016 and 0.013, respectively), cHL of the mixed 
1.0
0.8
0.6
0.4
0.2
0
0 0.2 0.4
1 – specificity
0.6 0.8 1.0
A
Se
ns
iti
vi
ty
1.0
0.8
0.6
0.4
0.2
0
0 0.2 0.4
FOXP3
CD68
1 – specificity
0.6 0.8
Granzyme B
PD-1
1.0
B
 Fig. 2.  A ROC curve of the prognostic performance of CD68-pos-
itive macrophage numbers in cHL. The area under the ROC of 
0.660 indicates that consideration of the CD68-positive macro-
phage number is 16% more accurate in predicting survival in cHL 
than a random guess (dotted line). The curve point (arrow) at a 
sensitivity of 0.74 (74%) and specificity of 0.65 (65%; 1 – specific-
ity = 0.35) is at the greatest distance from the reference line.
 B ROC curves of the prognostic performance of CD68-positive 
macrophage numbers compared to relative amounts of FOXP3-, 
granzyme B- and PD-1-positive tumor-infiltrating lymphocytes 
in cHL. The curve shape of CD68 differs from that in  A due to the 
consideration of these additional factors. Note the decreasing area 
under the ROC from granzyme B to CD68 and the reciprocal (in-
verse) deviation of the FOXP3 curve, reflecting its positive prog-
nostic significance. The larger area under the ROC points to gran-
zyme B-positive cell numbers as the most promising prognostic 
factor; while PD-1 has significant shortcomings with regard to 
specificity (note negative/inverse deviations up to coordinates 0.1; 
 0.0) but is the most sensitive marker (note that from coordinates 
0.4; 0.8 its ROC curve overbears all other curves), CD68 number 
determination is not better than a random guess (unlabeled, dot-
ted line) up to coordinates 0.1; 0.1. 
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Table 3.  Distribution of causes of death with respect to numbers 
of CD68-positive tumor macrophages
CD68+ tumor
macrophages
C ause of death
lym- 
phoma
second ma-
lignancy
cardiovascu-
lar disease
infec-
tion
trau-
ma
Increased 5 8 3 2 1
Decreased 5 3 3 0 0
p value 0.028
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cellularity subtype (p = 0.008), cHL without Epstein-Barr 
virus association (p  ! 0.001) and patients treated only 
with chemotherapy (p = 0.002), especially those treated 
with cyclophosphamide, vincristine, procarbazine and 
prednisone (COPP; p = 0.001), and was less pronounced, 
in patients treated with adriamycin, bleomycin, vinblas-
tine and dacarbazine (ABVD; p = 0.079) and with COPP 
plus RT (p = 0.019). However, the shape of the respective 
Kaplan-Meier curves also suggested a negative prognos-
tic effect of an increased number of CD68-positive tumor 
macrophages in the subgroups in which statistical sig-
nificance was not reached. Importantly, the prognostic 
effects of CD68-, PD-1- and granzyme B-positive cellular 
contents were cumulative ( fig. 4 ).
 In a multivariable analysis considering patient age, 
disease stage and numbers of FOXP3-, granzyme B- and 
PD-1-postive tumor-infiltrating lymphocytes, only age, 
in particular  6 55 years, appeared to be of independent 
prognostic significance for OS (p = 0.046). A combina-
tion background score considering all prognostically 
negative microenvironmental components, i.e. CD68-, 
PD-1- and granzyme B-positive cell numbers, was of in-
dependent prognostic significance (p = 0.002; relative 
risk 2.63, 95% CI 1.41–4.93) compared to age (p = not sig-
nificant; relative risk 2.07) and disease stage (p = not sig-
nificant; relative risk 1.31). Adding CD68 to PD1 and 
granzyme B made it possible to identify a subgroup of 
cHLs with an excellent prognosis if all cellular micromi-
lieu components were decreased (1 death with/from lym-
phoma out of 20 patients) as well as a group with a dismal 
prognosis if all components were increased (2 deaths 
with/from lymphoma and 6 deaths from a second malig-
nancy out of 11 patients).
 Discussion 
 Steidl et al.  [25] recently reported that increased CD68-
positive tumor macrophage numbers have a major im-
pact on the prognosis of cHL. Here, we present the first 
study to address the reproducibility of their findings. We 
were able to principally confirm the data of Steidl et al. 
 [25] as well as the findings of Ree and Kadin  [23] , report-
ed 25 years ago, in our collective, which was not specifi-
cally enriched for treatment failures. This lack of enrich-
ment for treatment failures as well as the application of 
the more specific PGM1 anti-CD68 antibody instead of 
the KP1 antibody, as applied by Steidl et al.  [25] , might be 
the primary reasons for the slightly lower CD68-positive 
tumor macrophage numbers observed in our collective. 
In addition, we refined the role of this single biomarker 
in the context of the cellular micromilieu of cHL. We ob-
served an adverse prognostic significance of an increased 
number of CD68-positive tumor macrophages with re-
spect to OS. This effect was particularly pronounced in 
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0.6
0.4
0.2
0
0 36 108 180 252 32472 144
11 dead/62 patients
19 dead/43 patients
p < 0.001
CD68-positive
macrophages
Follow-up (months)
O
ve
ra
ll 
su
rv
iv
al
216 288 360
++
+ ++ + +++++
++ +
++++
+
+ +
++ +++++
++++
+
++++
++
+
+ ++
+ + + +
++
+
<0.82%
>0.82%
1.0
0.8
0.6
0.4
0.2
0
0 36 108 180 252 32472 144
1 dead/20 patients
3 dead/23 patients
5 dead/19 patients
8 dead/11 patients
p < 0.001
CD68-, granzyme B-
and PD-1-positive
background cells
Follow-up (months)
O
ve
ra
ll 
su
rv
iv
al
216 288 360
+ + + +++++ ++ + +++ ++ +
+ + + +
+ ++ +++
+
+
+
++
+++ + ++ +
+ +++ + + ++
+
none increased
one increased
two increased
all increased
 Fig. 3. Kaplan-Meier OS curves of cHLs with respect to the num-
ber of CD68-positive tumor macrophages. The p value was calcu-
lated by applying the log-rank test. 
 Fig. 4. Kaplan-Meier OS curves of cHLs with respect to cellular 
background composition. The p value was calculated by applying 
the log-rank test. The total number of patients (n = 73) is lower 
than that in figure 3 (n = 105) due to uninformative TMA spots 
for granzyme B- and/or PD-1-positive cellular contents in 32
cases. 
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mixed cellularity cases, in patients younger than 55 years, 
in stage II and III disease and in cases without Epstein-
Barr virus association. With regard to treatment, espe-
cially patients treated by COPP-based therapy, either 
with or without RT, as well as those treated by chemo-
therapy alone (either COPP or ABVD), without RT, there 
was a negative prognostic effect of CD68-positive cell 
numbers. The advantages of our study are as follows: (1) 
no preselection of the cases, in particular no enrichment 
for treatment failures; (2) very long follow-up period (me-
dian 12 years); (3) ROC curve-based determination of 
prognostic cutoff values with both maximum specificity 
and sensitivity without the need for arbitrary cutoff 
scores; (4) extensive previous phenotypic cellular back-
ground and HRSC characterization of the studied collec-
tive  [18, 19, 26, 30] , and (5) distribution of cHL subtypes 
reflecting that of the general population.
 On the other hand, the limitations of our study include 
the following: (1) this was a retrospective study with a 
long period of sample collection (1974–2000) that could 
include possible bias due to different treatments applied 
within this period and (2) lack of data on International 
Prognostic Score and secondary treatment. Importantly, 
the first and the last point among the advantages as well 
as the first point among the disadvantages might explain 
why a prognostic effect with regard to DSS and RFS was 
not observable in our collective compared to that of Steidl 
et al.  [25] , the latter being enriched for treatment failures 
with a particularly low number of mixed cellularity cases.
 Beyond the general reproduction of the results of Steidl 
et al.  [25] , the new findings of our study are: (1) discovery 
in a general cHL collective of a cutoff score of 0.82% (for 
practical purposes 1%) CD68-positive tumor macro-
phages for OS prognostication, suggesting that at diag-
nostic determination the histopathologist should recog-
nize whether on average every 100th cell from the cellular 
background represents a CD68-positive macrophage; (2) 
CD68-positive cellular contents are prognostically rele-
vant only if assessed in HRSC-containing or -enriched 
areas (hot spots) rather than in whole tissue specimens; 
(3) CD68-positive tumor macrophage numbers correlate 
with a cellular background (low FOXP3/high granzyme 
B and PD-1 cellular background) that is usually associ-
ated with an unfavorable outcome in cHL  [16–19, 30] , and 
(4) a particular association of increased CD68-positive 
tumor macrophage numbers at diagnosis with deaths 
from second malignancies and infections. Other signifi-
cant correlations include that between CD68-positive tu-
mor macrophage numbers and patient age in cHL, as well 
as overrepresentation of cHLs with mixed cellularity and 
lymphocyte depletion in cases with increased CD68-pos-
itive macrophages, which is in agreement with observa-
tions from more than 2 decades ago  [23] .
 The reason for the observed prognostic significance of 
CD68-positive tumor macrophage contents with regard 
to cHL outcome are unknown, but it probably reflects a 
particular inflammatory tumor microenvironment or 
individual immunologic or immunogenetic imprinting 
 [31] . Direct effects of the respective cellular components 
can also be assumed. For example, it has been suggested 
that tumors may use the power of granzyme B-positive 
lymphocytes to their advantage, because mice lacking 
granzyme B clear tumor grafts more efficiently than do 
wild-type mice  [32] . At least in our collective, CD68-pos-
itive tumor macrophage numbers were not an indepen-
dent prognostic factor in cHL compared to age, disease 
stage and numbers of FOXP3-, granzyme B- and PD-1-
positive tumor-infiltrating lymphocytes. When consid-
ered together with other microenvironmental compo-
nents, namely granzyme-B- and PD-1-positive cells, 
CD68-positive cells considerably increased the specifici-
ty and sensitivity of prognosis in cHL independent of pa-
tient age or disease stage being a particular indicator of 
an increased risk for patients to die of a second malig-
nancy or infection. This supports our assumption that 
CD68-positive tumor macrophages represent an impor-
tant, but not exclusive, ‘player’ in the unfavorable micro-
environmental signature probably composed of a limited 
number of other cytotoxic and regulatory immune cells, 
the puzzling roles of which remain to be elucidated.
 To summarize, increased numbers of CD68-positive 
tumor macrophages indicate an adverse overall outcome 
in cHL. For the purpose of prognostication, CD68-pos-
itive cell numbers should be assessed in HRSC-rich
cHL areas. Increased CD68-positive tumor macrophage 
counts correlate with a cellular background (low FOXP3/
high granzyme B and PD-1 cells) that is usually associ-
ated with an unfavorable outcome in cHL. Prospective 
studies on cHL collectives treated with modern modali-
ties without selection bias are needed to establish the 
prognostic importance of the different microenviron-
mental components.
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